GLPGF News and Press, Galapagos Genomics Ord From 08/24/23

2023-08-24 10:55:38 ET More on Galapagos Galapagos NV ( GLPG ) Q2 2023 Earnings Call Transcript Galapagos to transfer drug discovery and research activities in France to NovAliX Galapagos stock dips as Jyseleca fails phase 3 trial as induction therapy in Crohn's ...

2023-08-04 16:30:18 ET Galapagos NV (GLPG) Q2 2023 Results Conference Call August 04, 2023 08:00 AM ET Company Participants Sofie Van Gijsel - Head, IR Paul Stoffels - CEO, Chairman, Interim Head, R&D Thad Huston - CFO and COO Michele Manto - Chief Commer...

Half-year 2023 key financials Group revenues of €328.8 million Jyseleca® net sales of €54.3 million Cash and current financial investments of €3.9 billion on 30 June 2023 Full year 2023 net sales guidance for Jyseleca® lowered to ...

Mechelen, Belgium; 15 June 2023, 22:01 CET ; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced the appointment of T had Huston as Chief Financial Officer (C F O) and Chief Operating ...

Mechelen, Belgium; 12 June 2023, 22:01 CET ; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that during its meeting of 12 June 2023 , the Board of Directors co-opted Dr. Susanne S chaffert as no n-executive indepe...

All 7 out of 7 eligible patients with relapsed/refractory c hronic l ymphocytic l eukemia ( rrCLL ) , with or without Richter’s T ransformation (RT) , responded to treatment (Objective Response Rate of 100%) 1 GLPG5201...

GLPG3667 is an investigational, novel, oral, reversible, and selective tyrosine kinase 2 (TYK2) inhibitor GLPG3667 is currently in development for the treatment of inflammatory and auto-immune diseases and, if approved, has the potential to be the first selective oral TYK2 inhibitor in de...

9 poster presentations and 3 abstracts publications reinforce Galapagos' commitment to immunology and the rheumatoid arthritis (RA) patient and healthcare professional community New analyses will be presented from long-term extension studies providing insights into filgotinib's ...

Mechelen, Belgium ; 5 M ay 2023 , 22 : 01 CET; regulated information – Galapagos NV (Euronext & NASDAQ : GLPG) announced today that its B oard of D irectors created 1 , 975 , 000 ...

2023-05-05 12:47:05 ET Galapagos NV (GLPG) Q1 2023 Earnings Conference Call May 05, 2023, 08:00 ET Company Participants Sofie Van Gijsel - Head, IR Paulus Stoffels - CEO, Chairman, Interim Head, R&D Bart Filius - President, COO & CFO Michele Manto - C...